Crispr Therapeutics Ag (CRSP) financials
Crispr Therapeutics Ag revenue and earnings by year
Crispr Therapeutics Ag's revenue was $3.51 million in the fiscal year to December 31, 2025, down 90.6% from the year before. Net income was -$582 million, -16569.8% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 4.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 37 | 371 | 1 | 915 | 1 | 290 | 3 | 41 | 5 |
| Revenue growth | -90.6% | -89.9% | 30885.5% | -99.9% | 127154.9% | -99.8% | 9169.8% | -92.4% | 693.9% | — |
| Operating income | -665 | -467 | -223 | -673 | 374 | -354 | 47 | -159 | -65 | -68 |
| Operating margin | -18933.6% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% |
| Net income | -582 | -366 | -154 | -650 | 378 | -349 | 67 | -165 | -68 | -23 |
| Net margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% |
| Diluted EPS | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.27 | $0.97 | -$3.43 | -$1.72 | — |
| Free cash flow | -346 | -145 | -270 | -533 | 457 | -257 | 50 | -99 | -78 | -56 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CRSP in Markets.
How Crispr Therapeutics Ag makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Collaboration Revenue | $10.0M | 98.2% |
| Grant | $181K | 1.8% |
See also: CRSP returns
No forecast, no recommendation. This page describes Crispr Therapeutics Ag from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.